You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
29 June 2015
Prothena Announces Addition of Seasoned Executive to Board of Directors
17 June 2015
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson’s Disease
16 June 2015
Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
12 June 2015
Prothena’s NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
9 June 2015
Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases
